Welcome To Enzychem
Clinical Pipeline
One deep-rooted belief we hold here at Enzychem Lifesciences is that any form of treatment should be accessible to patients all over the world. As we pursue to develop a global new drug, our team carries the important duty of ensuring EC-18’s efficacy backed up by comprehensive studies. Enzychem has commenced clinical trials in 2016, and since then, we have been conducting ongoing research in the drug’s effects on patients with one of various conditions.
Read More
Clinical Program
The global drug development program at Enzychem entails an extensive sequence of clinical studies on the safety and efficacy of EC-18 in various indications.
Read MoreLatest News
July 14, 2020
Enzychem Lifesciences Files IND Application to FDA for Phase 2 Study of EC-18 in Preventing Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 Pneumonia
Read More
May 18, 2020
Enzychem Lifesciences Appoints Duke Medical Coronavirus Task Force Expert Dr. Cameron Wolfe to Lead Development of EC-18 as a COVID-19 Therapeutic Drug
Read More
May 14, 2020
Enzychem Lifesciences Initiates Phase 2 Study for EC-18 in Preventing Acute Respiratory Distress Syndrome (ARDS) due to Novel Coronavirus Pneumonia
Read More
May 01, 2020
Enzychem Lifesciences Announces Publication of Preclinical Study of EC-18 in Gouty Arthritis in Frontiers in Immunology
Read More